Reuters Health Information: Gilead's pancreas cancer drug fails mid-stage study
Gilead's pancreas cancer drug fails mid-stage study
Last Updated: 2014-09-17
By Reuters Staff
(Reuters) - Gilead Sciences Inc said its experimental drug
did not significantly improve how long patients with a type of
pancreatic cancer lived without the disease worsening.
The mid-stage study evaluated the drug, simtuzumab, in
combination with chemotherapy, against a placebo plus
chemotherapy, in previously untreated patients with advanced
The study failed its main goal of improving
progression-free-survival (PFS). There was no statistically
significant difference in PFS between patients on simtuzumab and
those on the placebo, Gilead said on Wednesday.
Simtuzumab is also being tested for use in colorectal
cancer, myelofibrosis, idiopathic pulmonary fibrosis and liver
Last week, Gilead said the next generation version of its
$84,000 hepatitis C drug, Sovaldi, already under fire for its
record-breaking costs, was going to be even more expensive.
Separately, the biotechnology company also licensed Sovaldi
to seven India-based drugmakers that will sell far cheaper
versions of the drug in 91 developing nations.